Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur
Standard
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur : A Consensus Paper. / Wörmann, Bernhard; Bokemeyer, Carsten; Burmeister, Thomas; Köhne, Claus-Henning; Schwab, Matthias; Arnold, Dirk; Blohmer, Jens-Uwe; Borner, Markus; Brucker, Sara; Cascorbi, Ingolf; Decker, Thomas; de Wit, Maike; Dietz, Andreas; Einsele, Hermann; Eisterer, Wolfgang; Folprecht, Gunnar; Hilbe, Wolfgang; Hoffmann, Jürgen; Knauf, Wolfgang; Kunzmann, Volker; Largiadèr, Carlo R; Lorenzen, Sylvie; Lüftner, Diana; Moehler, Markus; Nöthen, Markus M; Pox, Christian; Reinacher-Schick, Anke; Scharl, Anton; Schlegelberger, Brigitte; Seufferlein, Thomas; Sinn, Marianne; Stroth, Matthias; Tamm, Ingo; Trümper, Lorenz; Wilhelm, Martin; Wöll, Ewald; Hofheinz, Ralf-Dieter.
In: ONCOL RES TREAT, Vol. 43, No. 11, 23.10.2020, p. 628-636.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur
T2 - A Consensus Paper
AU - Wörmann, Bernhard
AU - Bokemeyer, Carsten
AU - Burmeister, Thomas
AU - Köhne, Claus-Henning
AU - Schwab, Matthias
AU - Arnold, Dirk
AU - Blohmer, Jens-Uwe
AU - Borner, Markus
AU - Brucker, Sara
AU - Cascorbi, Ingolf
AU - Decker, Thomas
AU - de Wit, Maike
AU - Dietz, Andreas
AU - Einsele, Hermann
AU - Eisterer, Wolfgang
AU - Folprecht, Gunnar
AU - Hilbe, Wolfgang
AU - Hoffmann, Jürgen
AU - Knauf, Wolfgang
AU - Kunzmann, Volker
AU - Largiadèr, Carlo R
AU - Lorenzen, Sylvie
AU - Lüftner, Diana
AU - Moehler, Markus
AU - Nöthen, Markus M
AU - Pox, Christian
AU - Reinacher-Schick, Anke
AU - Scharl, Anton
AU - Schlegelberger, Brigitte
AU - Seufferlein, Thomas
AU - Sinn, Marianne
AU - Stroth, Matthias
AU - Tamm, Ingo
AU - Trümper, Lorenz
AU - Wilhelm, Martin
AU - Wöll, Ewald
AU - Hofheinz, Ralf-Dieter
N1 - © 2020 S. Karger AG, Basel.
PY - 2020/10/23
Y1 - 2020/10/23
N2 - BACKGROUND: 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side effects and the treatment-related mortality rate is 0.2-1.0%.SUMMARY: Among other risk factors associated with increased toxicity, a genetic deficiency in dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for the metabolism of FU, is well known. This is due to variants in the DPD gene (DPYD). Up to 9% of European patients carry a DPD gene variant that decreases enzyme activity, and DPD is completely lacking in approximately 0.5% of patients. Here we describe the clinical and genetic background and summarize recommendations for the genetic testing and tailoring of treatment with 5-FU derivatives. The statement was developed as a consensus statement organized by the German Society for Hematology and Medical Oncology in cooperation with 13 medical associations from Austria, Germany, and Switzerland. Key Messages: (i) Patients should be tested for the 4 most common genetic DPYD variants before treatment with drugs containing FU. (ii) Testing forms the basis for a differentiated, risk-adapted algorithm with recommendations for treatment with FU-containing drugs. (iii) Testing may optionally be supplemented by therapeutic drug monitoring.
AB - BACKGROUND: 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side effects and the treatment-related mortality rate is 0.2-1.0%.SUMMARY: Among other risk factors associated with increased toxicity, a genetic deficiency in dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for the metabolism of FU, is well known. This is due to variants in the DPD gene (DPYD). Up to 9% of European patients carry a DPD gene variant that decreases enzyme activity, and DPD is completely lacking in approximately 0.5% of patients. Here we describe the clinical and genetic background and summarize recommendations for the genetic testing and tailoring of treatment with 5-FU derivatives. The statement was developed as a consensus statement organized by the German Society for Hematology and Medical Oncology in cooperation with 13 medical associations from Austria, Germany, and Switzerland. Key Messages: (i) Patients should be tested for the 4 most common genetic DPYD variants before treatment with drugs containing FU. (ii) Testing forms the basis for a differentiated, risk-adapted algorithm with recommendations for treatment with FU-containing drugs. (iii) Testing may optionally be supplemented by therapeutic drug monitoring.
U2 - 10.1159/000510258
DO - 10.1159/000510258
M3 - SCORING: Review article
C2 - 33099551
VL - 43
SP - 628
EP - 636
JO - ONCOL RES TREAT
JF - ONCOL RES TREAT
SN - 2296-5270
IS - 11
ER -